Lotte Buys Bristol-Myers Plant for $160 Million in Health Foray
Bloomberg · 05/13 08:30
Bristol-Myers Targeted by Senior Democrat on Offshore Tax Deal
Bloomberg · 01/18 21:01
'Bloomberg Daybreak: Middle East' Full Show (01/12/2022)
Bloomberg · 01/12 09:14
Bristol Myers Is Very Focused on M&A, CEO Says
Bloomberg · 01/12 00:05
Catching up with a Bristol Myers Deal Hunter as the Virtual JPMorgan Conference Kicks Off 
Bloomberg · 01/10 18:07
Bristol-Myers Signs Cancer Deal With German Biotech Immatics
Bloomberg · 12/14/2021 13:02
Aurinia Extends Gain on Report of Bristol-Myers Approach
Bloomberg · 10/25/2021 13:55
Bristol Myers CEO on second quarter, infrastructure
Bloomberg · 07/28/2021 17:30
Bristol-Myers CEO on Delta Variant, Return of Office Workforce
Bloomberg · 07/28/2021 17:18
Biogen Decision Clarifies FDA Alzheimer’s Standard, Bristol Says
Bloomberg · 07/28/2021 13:44
Bristol Myers Strikes $1.6 Billion Pact for New Cancer Drug
Bristol Myers Squibb Co. has agreed to pay Agenus Inc. as much as $1.56 billion for the rights to a new kind of experimental drug that uses the body’s immune system to combat cancer.
Bloomberg · 05/18/2021 13:12
UPDATE 1-FDA approves Bristol-Myers' gene therapy for white blood cell cancer · 02/05/2021 21:17
Bristol Myers 4th quarter profit tops Street view on strong sales from Celgene drugs · 02/04/2021 11:59
Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash
Jounce therapeutics is a differentiated player in the hot immuno-oncology sector.JNCE stock has not been fairly priced after its newly struck partnership with Gilead Sciences, making it a compelling buy for the short term.JNCE's drug discovery engine continues to impress, potentially making it an equally compelling pick for the longer term.
Seekingalpha · 09/11/2020 18:06
European advisory group backs Celgene's ozanimod for type of multiple sclerosis
seekingalpha · 03/27/2020 18:35
GAMCO Investors Exits Viacom, Spark Therapeutics · 02/28/2020 15:33
Ronald Muhlenkamp's Firm Exits Celgene, Trims Gilead Position · 02/26/2020 19:22
Ronald Muhlenkamp's Firm Buys 3 Stocks in 4th Quarter · 02/21/2020 17:13
David Rolfe's Firm Cuts Apple, Visa · 02/19/2020 17:09
Gilead an acquisition target? Deep pockets required
seekingalpha · 02/07/2020 22:11
Webull provides a variety of real-time CELG stock news. You can receive the latest news about Celgene through multiple platforms. This information may help you make smarter investment decisions.
About CELG
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.